HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Hopes To Continue Appellate Streak Following Whopping $4.69bn Talc Verdict

This article was originally published in The Rose Sheet

Executive Summary

Counsel for 22 women who blame J&J talcum powders for their ovarian cancer took a new approach in this latest case in St. Louis Circuit Court, arguing that asbestos in the firm’s talc is the culprit, rather than talc itself. J&J is confident in its ability to overturn the verdict, which it characterized as biased and unfounded.

You may also be interested in...



J&J’s Talc Subsidiary Not ‘Financially Distressed’ Enough For Bankruptcy – Third Circuit

The J&J company holding the firm’s liabilities relating to talc litigation, which declared bankruptcy in 2021 shortly after its formation, had its Chapter 11 petition denied by the Third Circuit on 30 January. Attorneys weigh in on the implications for J&J and wider industry.

J&J's CEO Gorsky Steps Aside With Duato Named His Successor

J&J's CEO Alex Gorsky is stepping down after almost 10 years in the role and will be replaced by vice chairman of the executive committee Joaquin Duato. 

J&J Appeal Of $2bn Talcum Powder Judgment Denied By US Supreme Court

The Supreme Court said on 1 June that it would not review a $2bn verdict in Missouri for 22 women who alleged links between ovarian cancer and asbestos-tainted talc in Johnson’s Baby Powder. J&J believes the US' top court passed on an "extraordinary opportunity" that "leaves unresolved significant legal questions that state and federal courts will continue to face."

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel